Full mechanism, in text

How bone is broken down and rebuilt

1 · RANKL/OPG ratio

Osteoblasts secrete both , which activates bone-resorbing osteoclasts, and OPG, a decoy receptor that binds RANKL, so the RANKL/OPG ratio decides the net resorption rate.Bone isn't stone, it's a continuously remodelled living tissue.

Two key cell types:

· Osteoblast: secretes osteoid + osteocalcin → mineralisation → builds bone
· Osteoclast: giant multinucleated cell, secretes acid + cathepsin K → digests bone matrix → resorbs bone

Osteoblast controls both sides — this is the key insight of the RANK//OPG system (Simonet 1997 + Hofbauer 1999 classics):

· Osteoblast secretes RANKL (Receptor Activator of Ligand) → activates osteoclast precursors → resorption
· The same osteoblast also secretes OPG (Osteoprotegerin) → decoy receptor binds RANKL → prevents it from binding RANK → protects bone

RANKL/OPG ratio → decides net resorption rate:

· RANKL ≫ OPG: many osteoclasts, resorption > formation → bone loss
· OPG ≫ RANKL: osteoclasts strangled by decoy, resorption < formation → bone preserved / gained

Regulators:

↑ RANKL (pro-resorption):

· High (hyperparathyroidism) — chronic sustained PTH → ↑ RANKL → bone loss
· Glucocorticoids (chronic prednisone ≥ 5 mg/day ≥ 3 months) — directly ↑ RANKL + ↓ OPG → GIOP (steroid-induced osteoporosis)
· + IL-1 + (chronic inflammation) — rheumatoid arthritis / / elderly inflammatory milieu
· Menopause (estrogen ↓): estrogen normally suppresses RANKL + promotes OPG → menopausal plunge → bone loss is fastest in the first years after menopause

↑ OPG (pro-protection):

· Mechanical load (strength training + high-impact) — osteoblasts sense stress → ↑ OPG
· Estrogen () (keeps OPG up and RANKL down) + androgen (T)

Not switches for these signals but materials / cofactors:

· Calcium + protein + magnesium — building materials
· Vitamin D — helps the gut absorb calcium
· Vitamin — cofactor for γ-carboxylating osteocalcin + MGP

Clinical translation — post-menopausal window:

· Estrogen plunges in menopause year 1 → RANKL ↑ + OPG ↓ → the RANKL/OPG ratio rises
· Bone loss is fastest in the first years after menopause
· Window interventions: calcium + D + strength + (if appropriate) / selective drugs
· Key: it's not wait until age 65 , it's start intervening in menopause year 1

2 · osteoclast activation

Once binds RANK on precursor cells, they mature into osteoclasts, which seal onto bone, pump in H⁺ to dissolve hydroxyapatite, and digest the collagen matrix with cathepsin K. → RANK → osteoclast differentiation + activation:

· Osteoclast precursors (monocyte/macrophage lineage) express RANK receptor
· RANKL binds RANK → downstream + AP-1 → differentiation → multinucleated fusion → mature osteoclast
· M-CSF (Macrophage Colony-Stimulating Factor) is the cooperative signal

Activated osteoclast resorption mechanism:

· Attaches to bone surface → forms ruffled border (sealed cavity like an acid pit)
· Proton pump (V-ATPase) + chloride channel (CLC-7): pumps H⁺ into the sealed cavity → pH ~ 4.5 (extremely acidic)
· Hydroxyapatite (Ca₁₀(PO₄)₆(OH)₂) dissolves in acid → releases Ca²⁺ + PO₄³⁻
· Simultaneously secretes cathepsin K + MMP-9: digests collagen matrix
· Released Ca + PO₄ return to blood

Normal vs pathological:

· Normal resorption-formation coupling: osteoclast carves out Howship's lacuna → osteoblast fills back → ~ 10% of total bone renewed per year
· Post-menopausal / GIOP / chronic inflammation: resorption rate ↑↑ + formation flat → net loss
· Paget's disease: overactive osteoclasts → disorganised bone architecture

Morphological identification:

· Mature osteoclast: 10-100 µm, multinucleated (5-20+), highly polarised
· Location: cortical bone inner surface (endosteum) + trabecular bone surface
· Lifespan: 2-3 weeks, then self-apoptosis / clearance

Closing the loop with mineral imbalance + acid-base:

· Chronic metabolic acidosis (caused by disease, such as chronic kidney disease) → bone mobilised as buffer (resorption releases calcium carbonate) → long-term bone loss
· An acid-leaning diet is not this kind of acidosis: pooled results from the most rigorous calcium-balance studies show that when changing protein intake raised the diet acid load, urine calcium went up, but whole-body calcium balance and a bone resorption marker did not change
· progression → chronic acidosis + Ca/P disturbance + vitamin D deactivation → CKD-MBD bone disease

Position map of targeted drugs:

· Bisphosphonates: directly ingested by osteoclasts → inhibit FPPS → apoptosis (next step in detail)
· Denosumab (Prolia): anti-RANKL mAb → blocks upstream differentiation signal → osteoclasts don't form
· Romosozumab (Evenity): anti-sclerostin mAb → simultaneously promotes formation + suppresses resorption → bidirectional
· analogues (Teriparatide / Abaloparatide): intermittent PTH → conversely promotes formation (opposite to chronic sustained PTH causing loss — dose + rhythm decide direction)
· Cathepsin K inhibitor (Odanacatib): inhibits enzyme without killing osteoclast — withdrawn (cardiovascular side effects)

3 · bisphosphonate uptake

Bisphosphonates wait on the bone surface until osteoclasts ingest them while resorbing, which cripples their cytoskeleton, collapses the ruffled border and drives them into apoptosis.Bisphosphonates — half-century-old drugs, still first-line for osteoporosis.

Structure + bone affinity:

· Core: P-C-P backbone (like natural pyrophosphate P-O-P but biologically non-hydrolysable)
· R side chain with nitrogen (N) (N-bisphosphonates: alendronate / risedronate / zoledronate) — potent, first-line
· Non-N (etidronate / clodronate) — weak, earlier-generation
· Phosphate groups have extreme affinity for hydroxyapatite (HA) — magnetised to bone surface

Administration + absorption:

· Oral bisphosphonate: alendronate 70 mg / week
Bioavailability < 1%: must be fasting + large glass of water + stand for 30 minutes (avoids oesophageal irritation + Ca/Mg chelation)Oesophageal irritation: not standing → reflux → oesophagitis· IV bisphosphonate: zoledronate 5 mg / year IV (Black 2007 NEJM HORIZON)
Preferred for poor adherence; one shot covers a yearA flu-like reaction is common in the days after the first IV dose: antipyretics + fluids help
Mechanism (4 steps):

Step 1: Deposition on bone surface

· Bisphosphonate enters blood → rapidly adsorbed onto hydroxyapatite (binds to bone surfaces quickly)
· Very long half-life: years to over a decade once deposited
· Non-deposited fraction excreted by kidney (no hepatic metabolism → use cautiously in )

Step 2: Silent latency on bone surface

· Bisphosphonate that hasn't penetrated deep trabecular bone has almost no systemic effect
· Until osteoclast activation + resorption of bone surface

Step 3: Osteoclast ingests bisphosphonate-laden bone

· During resorption, osteoclasts accidentally ingest bisphosphonate-loaded hydroxyapatite
· Acid pit pH 4.5 → bisphosphonate released into osteoclast
· N-bisphosphonates: inhibit FPPS (farnesyl pyrophosphate synthase) → interrupt mevalonate pathway → small GTPases (Rho / Rac / Rab) can't be prenylated → cytoskeleton + vesicle trafficking collapse
· Non-N bisphosphonates: incorporated into pseudo- (AppCp) → direct toxicity

Step 4: Osteoclast apoptosis

· Ruffled border collapses → resorption capacity gone → apoptosis
· New osteoclasts keep being generated, but every newly-matured cell repeats the same fate

Clinical effects:

· Bone resorption markers (CTX, NTX): fall clearly within months
· : rises gradually
· Fractures: with zoledronate (HORIZON, Black 2007), vertebral fractures fell 70% and hip fractures 41% in relative terms (next step)

Long-term side effects (≥ 5 years use):

· Osteonecrosis of jaw (ONJ): rare, with higher risk after dental surgery such as extractions; talk to the doctor before planned dental work
· Atypical femoral fracture (AFF): long-term > 5 years, unusual locations — drug holiday of 1-2 years reduces risk
· Oesophagitis + : oral, strict standing reduces
· Flu-like reaction (IV first dose)
· Hypocalcaemia: before use must have > 20 ng/mL (50 nmol/L) + adequate calcium intake

Course:

· 3-5 year review → drug holiday 1-2 years → re-evaluate
· High-risk (recent fracture / T ≤ -3.0): continue / switch drug
· CKD < 30: bisphosphonates are generally not recommended → Denosumab can be considered (no renal dose adjustment, but a higher risk of severe low calcium: correct calcium and vitamin D first, check calcium afterwards)

4 · BMD recovery

Denosumab binds so osteoclasts never form, and its trial cut fractures about as much as the zoledronate trial, but stopping it brings a rebound and needs a bisphosphonate bridge.Clinical outcomes (key trials):

Black 2007 NEJM HORIZON (zoledronate IV):

· Postmenopausal women with osteoporosis, 3 years, 5 mg IV once a year
· Vertebral fractures 70% lower in relative terms
· Hip fractures 41% lower

Cummings 2009 NEJM FREEDOM (Denosumab):

· Postmenopausal women with osteoporosis, 3 years, 60 mg SC every 6 months
· Vertebral fractures 68% lower in relative terms
· Hip fractures 40% lower

Denosumab mechanism:

· Fully human IgG2 mAb → directly binds → prevents RANK activation → osteoclasts never form
· Completely different position from bisphosphonates — upstream cutoff vs downstream clearance
· Advantages: no IV infusion, no oral oesophageal restrictions and no renal dose adjustment (but people with advanced kidney disease have a higher risk of severe low calcium, see the warnings below)
· Critical warning: rebound phenomenon — stopping → multiple vertebral fracture risk within 6-12 months
· Solution: stopping Denosumab must be bridged with a bisphosphonate (zoledronate 1 shot) — can't simply stop

Bridging / sequential treatment philosophy:

· Different drugs act at different mechanistic positions, can be combined / sequenced
· Typical flow (severe osteoporosis):
1. Romosozumab 12 months (bidirectional: pro-formation + anti-resorption)
2. → Denosumab 1-2 years (maintain upstream cutoff)
3. → Zoledronate IV (long-term deposition + reduce rebound)
4. → Drug holiday + every 2 years

Common prescribing logic:

First-line:

· Alendronate 70 mg/week (oral) — cheap, strong evidence
· Zoledronate 5 mg/year IV — for poor adherence

Second-line / when first-line unsuitable:

· Denosumab — / oesophageal issues / high adherence risk
· Risedronate / Ibandronate — alendronate intolerance

Severe / multiple fractures:

· Romosozumab → bisphosphonate (bidirectional + long-term)
· Teriparatide → bisphosphonate (intermittent pro-formation + sequencing)

Contraindications / warnings:

· < 30: bisphosphonate contraindicated → Denosumab can be considered, but the risk of severe low calcium is higher, so it needs a doctor assessment and calcium monitoring
· Prior CV disease: avoid Romosozumab (a trial showed a slight signal of more cardiovascular events)
· Planning pregnancy + lactation: bisphosphonate absolutely contraindicated (crosses placenta + long half-life)

Don't forget non-drug measures:

· Calcium 1000-1200 mg/day + vitamin D 800-1000 /day
· Protein 1.0-1.2 g/kg/day
· Strength training 2-3×/week + balance training
· Stop smoking + limit alcohol + fall prevention

Drug = ultimate misconception:

· Drugs are only initiated when already diagnosed + high-risk
· The vast majority of bone health is decided by: building the foundation at 35-50 + early menopausal intervention + lifelong nutrition + exercise
· No drug can fully replace the mechanical stimulus of strength training on

Full mechanism, in text

1 · RANKL/OPG ratio

2 · osteoclast activation

3 · bisphosphonate uptake

4 · BMD recovery

RANKL/OPG balance + bisphosphonate mechanism

Full mechanism, in text

1 · RANKL/OPG ratio

2 · osteoclast activation

3 · bisphosphonate uptake

4 · BMD recovery

RANKL/OPG balance + bisphosphonate mechanism